Dr. Struthers is a founder of Crinetics. Prior to Crinetics, he was senior director and head, endocrinology and metabolism at Neurocrine Biosciences. At Neurocrine, he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists. This resulted in a first-in-class compound, elagolix, which has demonstrated safety and efficacy in over 40 clinical trials totaling more than 3,000 patients. Prior to Neurocrine, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. Dr. Struthers is an author of more than 75 scientific publications. He holds Ph.D. in physiology and pharmacology from the University of California, San Diego.
Suppression of gonadotropins and estradiol in premenopausal women by oral administration of a nonpeptide GnRH antagonist (elagolix).
Struthers RS, Nicholls AJ, Grundy J, Chen T, Jimenez R, Yen SS, Bozigian HP. Journal of Clinical Endocrinology and Metabolism. 2009; 94:545-51.
Non-peptide gonadotropin-releasing hormone receptor antagonists.
Betz SF, Zhu YF, Chen C, Struthers RS. Journal of Medicinal Chemistry. 2008; 51:3331-48.
Differential desensitization, receptor phosphorylation, beta-arrestin recruitment and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7.
Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS. Journal of Biological Chemistry. 2004; 279:23214-22.
Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant.
Struthers RS, Vale WW, Arias C, Sawchenko PE, Montminy MR. Nature. 1991; 350:622-4.